Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Anthera gets inflammation program from Lilly and Shionogi

Executive Summary

Anthera Pharmaceuticals (therapeutics for inflammatory diseases) has licensed worldwide development and commercialization rights (excluding Japan) to a pipeline of preclinical and clinical anti-inflammatory compounds developed by Eli Lilly and Shionogi under a previous agreement. Anthera provided the pharma companies with an undisclosed sum of Anthera equity.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies